Werewolf Therapeutics merges with Ambros in $150M deal to advance non‑opioid painkiller for rare limb injury syndrome

Werewolf Therapeutics and Ambros Therapeutics announced a merger valued at $150 million, creating a new company that will retain the Ambros name.

The deal includes a private placement to fund the development of Ambros’s non‑opioid painkiller neridronate for complex regional pain syndrome type 1, supporting a Phase 3 trial and regulatory filing through early 2029.

The combined entity will keep Ambros’s leadership, with CEO Jay Hagan, and the neridronate program already holds FDA breakthrough therapy, fast track and orphan drug designations.